GATA3 zinc finger 2 mutations reprogram the breast cancer transcriptional network

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• GATA3 is frequently mutated in breast cancer.
• The functional impact and clinical relevance of GATA3 mutations are poorly understood, with a prevailing assumption of loss-of-function.
• Lack of detailed mechanistic insight into how GATA3 mutations affect the breast cancer transcriptional network.

Purpose of the Study:

• To investigate the molecular and clinical features associated with GATA3 mutations in breast cancer.
• To elucidate the mechanistic impact of specific GATA3 mutations on gene expression and cellular function.
• To determine if different GATA3 mutations have distinct functional consequences.

Main Methods:

• Development of a novel classification scheme for GATA3 mutations.
• Creation of an engineered breast cancer cell line with a mutated GATA3 second zinc finger (ZnFn2) using CRISPR-Cas9.
• Analysis of gene expression and GATA3 binding patterns in wild-type versus mutant cell lines.

Main Results:

• A new classification identified distinct clinical features for patients with mutations in the GATA3 ZnFn2.
• Mutation of one GATA3 ZnFn2 allele resulted in loss of GATA3 binding and decreased expression of target genes, including Progesterone Receptor.
• Conversely, altered GATA3 binding at other loci correlated with increased gene expression, particularly in genes associated with epithelial to mesenchymal transition.

Conclusions:

• GATA3 mutations are not functionally equivalent in breast cancer.
• Mutations in the GATA3 ZnFn2 domain exhibit dual gain- and loss-of-function mechanisms.
• These distinct functional impacts of GATA3 mutations influence breast cancer progression and molecular subtypes.